利用GEO及TCGA数据集分析SMARCA1在胃癌中的表达及其临床意义#br#

目的探讨基因表达汇编（GEO）及癌症和肿瘤基因表达图谱（TCGA）数据集中胃癌组织的SMARCA1表达情况及其与胃癌临床病理特征和预后的关系。方法利用GEO和TCGA数据集汇总胃癌相关数据，下载胃癌组织SMARCA1表达数据及临床病理参数。分析SMARCA1表达与胃癌临床病理学特征和总生存期（OS）的关系；采用基因集富集分析（GSEA）预测SMARCA1相关的基因通路。结果在GSE62254数据集中，SMARCA1表达与T分期有关（P=0022），而与TNM分期、性别、年龄和N分期均无关（P＞005）。在TCGA数据集中，SMARCA1表达与T分期、性别、年龄、N分期、TNM分期和组织学分级均无关（P＞005）。GSE62254数据集中，SMARCA1高、中及低表达组胃癌患者的中位OS分别为364个月、894个月和未达（P=0001）；TCGA数据集中，SMARCA1高、中及低表达组胃癌患者的中位OS分别为237个月、294个月和562个月（P=0033）。GSEA结果显示，SMARCA1高表达样本富集了K Ras、Akt、BMI 1和mTOR通路等基因集。结论胃癌组织中SMARCA1的表达与T分期有关，高表达患者的预后不良，可作为潜在评估胃癌预后的分子标志物。

Analysis of SMARCA1 expression and its clinical significance in gastric cancer with databases of GEO and TCGA

ObjectiveTo investigate the expression of SMARCA1 and clarify the clinical significance and prognostic value of SMARCA1 of gastric cancer in the Gene Expression Omnibus（GEO） and The Cancer Genome Atlas（TCGA） datasets.MethodsSMARCA1 expression and its clinical information were downloaded from GEO and TCGA datasets. The influence of SMARCA1 expression on clinical pathological factors and overall survival（OS） were analyzed and gene set enrichment analysis（GSEA） was used to predict the SMARCA1 related related gene signaling pathway.ResultsThe expression of SMARCA1 was associated with T stage in GSE62254 dataset（P=0022）， but not related to gender， age， TNM stage and N stage in GSE62254（P＞005）. In TCGA dataset， SMARCA1 was not related to gender， age， TNM stage， T stage, N stage and histology classification. In the aspect of survival analysis， the median OS of high， medium and low levels of SMARCA1 expression were 364 months， 894 months and not achieved in GSE62254（P=0001）； the median OS of high， medium and low levels of SMARCA1 expression were 237 months， 294 months and 562 months in TCGA（P=0033）. GSEA showed that the expression of SMARCA1 could regulate gene sets involving K Ras， Akt， BMI 1 and mTOR signaling pathway.ConclusionSMARCA1 was related to T stage in gastric cancer， and its high expression was associated with poor prognosis. It could be a polential molecular marker for evaluating the prognosis of gastric cancer.